Nymox Pharmaceutical (NYMX) Reports Statistically Significant Data for NX-1207 in BPH
Tweet
Share
E-mail
Nymox Pharmaceutical Corporation (Nasdaq: NYMX) is pleased to report on the presentation of new positive data at a high-level symposium and panel discussion held Sunday at the Annual Meeting of the American Urological Association in Atlanta, GA. The symposium was held between 3:00 and 4:00 pm EDT on Sunday. The well-attended symposium highlighted the ongoing clinical development program for NX-1207 for the treatment of benign prostatic hyperplasia (BPH) and featured expert panel discussions on the new therapy. The symposium, "Clinical studies of NX-1207: Phase 3 injectable for BPH" was chaired by Ronald F. Tutrone Jr., MD, FACS of Towson, MD. Panel members included Barton Wachs, MD, FACS of Long Beach, CA, Nicholas Franco MD of Naples, FL and Mohamed Bidair MD of San Diego, CA.
A new research report was presented at the NX-1207 symposium, authored by Dr. Barton Wachs, Dr. Sheldon Freedman of Las Vegas, NV, Dr. Barrett Cowan of Denver, CO, and Dr. Neal Shore of Myrtle Beach, SC. The new data concerned outcome analyses of single-injection NX-1207 after 4 ½ years in 45 patients. Subjects in the NX-1207 2.5 mg cohort had mean improvements in their BPH symptoms that reached statistical significance (p < .0001). According to the report "NX-1207 is an office-based" procedure involving only a few minutes to administer associated with minimal discomfort and no catheter requirement," and "results at 52-56 months after a single treatment indicate statistically significant symptomatic improvement and a very acceptable safety profile."
A new research report was presented at the NX-1207 symposium, authored by Dr. Barton Wachs, Dr. Sheldon Freedman of Las Vegas, NV, Dr. Barrett Cowan of Denver, CO, and Dr. Neal Shore of Myrtle Beach, SC. The new data concerned outcome analyses of single-injection NX-1207 after 4 ½ years in 45 patients. Subjects in the NX-1207 2.5 mg cohort had mean improvements in their BPH symptoms that reached statistical significance (p < .0001). According to the report "NX-1207 is an office-based" procedure involving only a few minutes to administer associated with minimal discomfort and no catheter requirement," and "results at 52-56 months after a single treatment indicate statistically significant symptomatic improvement and a very acceptable safety profile."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Space-Eyes names four directors ahead of planned Nasdaq listing
- Quantum X Labs reports AI decoder gains on Google quantum dataset
- AMC Robotics raises up to $2.1M via warrant inducement deal
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
